The Latest Breaking News from FDA

Some insurances, including the government-run Medicare, refused to pay for the drug until it received full approval.

Eisai Co.’s Alzheimer’s drug Leqembi gained full approval from U.S. regulators Thursday, a move expected to widen access to the first drug cleared based on its ability to slow progression of the mind-robbing disease.

Eisai and Biogen's Leqembi is the first drug to slow Alzheimer's progression to receive full FDA approval.

U.S. officials have granted full approval to a closely watched Alzheimer’s drug for patients with early stages of the disease

The first drug found to slow the progression of Alzheimer's disease has been granted full approval by the Food and Drug Administration.

The drug Leqembi targets plaque buildup in the brain, and it is approved for people in the early stages of the disease.

Health officials are endorsing two new vaccines against respiratory syncytial virus (RSV) for older Americans, alongside flu and Covid-19 vaccines, although there are uncertainties about the risks

With the growing prevalence of chronic conditions, an aging population, widespread adoption of digital technologies, and several R&D efforts, the pharmaceutical industry is poised for exponential growth and expansion. So, let’s compare leading pharma stocks AbbVie (ABBV) and Pfizer (PFE) to identify which is a better investment now. Keep reading….

FDA approves new test, which has been widely celebrated as a small victory in the fight to make childbirth safer in the US

Vaccines to stave off the flu, a new COVID variant and now, respiratory syncytial virus could help avert another tripledemic this fall. Unless the public is too crisis-fatigued to care.

The idea seems simple enough.